retatrutide phase 2 trial weight loss just delivered the first top-line 3 results for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 Retatrutide Phase 3: 60% Achieved

But dig deeper into the clinical data, the receptor pharmacology, and the real-world side effect profiles, and these two treatments diverge in ways that matter enormously for researchers trying to decide between them

GI events were most common (nausea, vomiting, decreased appetite)

By hitting all three of these pathways, Retatrutide creates a powerful, multi-pronged attack on excess body fat and metabolic dysfunction

-Compounded products are not clinically evaluated for safety or efficacy

This group will be facilitated through a fat-affirming, weight stigma lens that prioritizes the demonstrated history of risk and harm associated with intentional weight-loss, including GLP-1s